CDRH Task Force Stirs Debate About FDA's Comparative-Effectiveness Role
This article was originally published in The Gray Sheet
Executive Summary
FDA stakeholders debated Feb. 9 whether it is appropriate for the agency to compare the effectiveness of new devices to the status quo as part of its pre-market reviews
You may also be interested in...
Device Firms Seek Definition Of "New Science," As FDA Mulls Policy Changes
FDA must better define what it considers "new science" when deciding how to incorporate emerging data into product reviews and post-market surveillance, and must vet the data carefully before reacting, device companies say
Device Firms Seek Definition Of "New Science," As FDA Mulls Policy Changes
FDA must better define what it considers "new science" when deciding how to incorporate emerging data into product reviews and post-market surveillance, and must vet the data carefully before reacting, device companies say
FDA Eyes The Future: 2010 Workshop To Address Integration Of "New Science"
FDA's device center will hold a public workshop in February to help formulate a strategy for integrating "new science" into its regulatory decisions